Related references
Note: Only part of the references are listed.Chronic inflammation and cancer: suppressing the suppressors
Michal Baniyash et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Simon J. Dovedi et al.
CANCER RESEARCH (2014)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells
Jamma Trinath et al.
BLOOD (2013)
Interleukin-1β Promotes Skeletal Colonization and Progression of Metastatic Prostate Cancer Cells with Neuroendocrine Features
Qingxin Liu et al.
CANCER RESEARCH (2013)
Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer
Jaikumar Duraiswamy et al.
CANCER RESEARCH (2013)
Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity
Aurelien Marabelle et al.
CLINICAL CANCER RESEARCH (2013)
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Joel Crespo et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Local targets for immune therapy to cancer: Tumor draining lymph nodes and tumor microenvironment
Marieke F. Fransen et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Algisyl-LVR™ with coronary artery bypass grafting reduces left ventricular wall stress and improves function in the failing human heart
Lik Chuan Lee et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells
Erin E. West et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Blockade of programmed death receptor-1 signaling restores expression of mostly proinflammatory cytokines in anergic cytomegalovirus-specific T cells
J. Dirks et al.
TRANSPLANT INFECTIOUS DISEASE (2013)
Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice
Hacer Sahin et al.
HEPATOLOGY (2012)
Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells
Ilona Kryczek et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Alginate: Properties and biomedical applications
Kuen Yong Lee et al.
PROGRESS IN POLYMER SCIENCE (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
New insights into chronic inflammation-induced immunosuppression
Julia Kanterman et al.
SEMINARS IN CANCER BIOLOGY (2012)
Know thy enemy Why are tumor-infiltrating regulatory T cells so deleterious?
Andrea Facciabene et al.
ONCOIMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
PGE2-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment
Natasa Obermajer et al.
CANCER RESEARCH (2011)
Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody
Marieke F. Fransen et al.
CLINICAL CANCER RESEARCH (2011)
Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma
Amir S. Gendy et al.
JOURNAL OF PEDIATRIC SURGERY (2011)
Measurement of cyclooxygenase inhibition using liquid chromatography-tandem mass spectrometry
Hongmei Cao et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2011)
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
John Stagg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Selective COX-1 Inhibition: A Therapeutic Target to be Reconsidered
M. G. Perrone et al.
CURRENT MEDICINAL CHEMISTRY (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Recent advances and hurdles in melanoma immunotherapy
Camilla Jandus et al.
PIGMENT CELL & MELANOMA RESEARCH (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Autologous chondrocyte implantation in a novel alginate-agarose hydrogel - Outcome at two years
T. A. S. Selmi et al.
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME (2008)
Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib
Luc Yves Dirix et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression
Stephanie K. Bunt et al.
CANCER RESEARCH (2007)
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy
Fumihiko Tsushima et al.
BLOOD (2007)
Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis
E. A. Silva et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Sergio A. Quezada et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer
S Sharma et al.
CANCER RESEARCH (2005)
Immunosuppressive networks in the tumour environment and their therapeutic relevance
WP Zou
NATURE REVIEWS CANCER (2005)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells
WP Zou et al.
NATURE MEDICINE (2001)
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
G Steinbach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
